SPI-452

SPI-452 is a small molecule inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, originally developed by Sequoia Pharmaceuticals as a pharmacokinetic enhancer (PKE). By inhibiting CYP3A4, the primary enzyme responsible for the metabolism of many drugs, SPI-452 was intended to "boost" the blood levels and extend the half-life of co-administered medications, particularly those used in the treatment of HIV/AIDS or other immune-related conditions. In Phase I clinical trials involving healthy volunteers, SPI-452 demonstrated a significant capacity to increase the minimum plasma concentrations (Cmin) of partner drugs. However, the development of SPI-452 has since been discontinued.